EUCTR2011-005856-32-ESActive, not recruitingPhase 1
Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathyresistant to conventional treatment
Fundación Progreso y Salud0 sites9 target enrollmentStarted: January 27, 2012Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 9
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Both men and women between 18 and 70 years.
- •-Patient with active lupus nephritis, previously treated with the following immunosuppressive unless contraindication: cyclophosphamide, azathioprine and mycophenolate (sodium or mophetil), who have not received rituximab in the two previous years, in whom regime was ineffective at least 3 months after treatment, or who experienced relapse during this time.
- •- Informed consent form signed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
Exclusion Criteria
- •-Active/sepsis serious infections
- •-Known neoplasia
- •- Heart failure with III/IV functional class
- •-Pregnancy
- •-Known anaphylaxis to the product
- •-Cardiovascular disease or uncontrolled hypertension
- •-Chronic hepatitis B
- •-Serious Citopenia (granulocytes < 500/mm3, further < 10000/mm3)
- •-Immunodeficiency (CVI, IgA deficiency)
- •-Infection with HIV
Investigators
Similar Trials
Recruiting
Phase 3
Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone.focal segmental glomerulosclerosisidiopathic nephrotic syndromeminimal change disease10029149NL-OMON44222Radboud Universitair Medisch Centrum40
Active, not recruiting
Phase 1
Comparison of rituximab with prolonged treatment with prednisone in patients with idiopathic nephrotic syndromeEUCTR2017-003366-27-NLRadboud University Nijmegen Medical Center40
Not yet recruiting
Not Applicable
Comparison between single dose and multiple dose Rituximab in idiopathic membranous nephropathyCTRI/2020/11/029094RS Medical College and Hospital
Recruiting
Phase 1
The effects of Rituximab and CyclosporineSteroid-resistant nephrotic syndrome.IRCT20240614062128N1Ghoum University of Medical Sciences76
Not yet recruiting
Not Applicable
A study comparing Rituximab/Bendamustin (RB) alternating with Rituximab/Bendamustin/Cytarabin (RBAC) with Rituximab/Bendamustin (RB) therapy in elderly patients with mentle cell lymphomaKCT0007009Samsung Medical Center90